Viking's Trial Press Release Sends VK2735 Shares Soaring
Created on
Last updated
Viking Therapeutics issued a clinical trial press release confirming its GLP-1/GIP candidate VK2735 helped patients maintain weight loss, including those on a once-monthly dosing schedule.
The announcement triggered a sharp rally in Viking shares, as investors weigh the drug's competitive positioning against Eli Lilly's Zepbound in the fast-growing obesity treatment market.
Biotech press releases like this remain key volatility drivers for equity and options traders tracking the GLP-1 sector's next earnings and regulatory catalysts.